The combination of disease-modifying anti-rheumatic drugs (DMARDs) and the development of tumour necrosis factor (TNF) inhibitors have for the first time been shown to induce the clinical remission of RA and delay or halt the clinical and radiological progression of the disease, thus improving the quality of life of many patients[1]. Here, TNF is linked to rheumatoid arthritis.